Disparities in biomarker-targeted therapy for resected NSCLC

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Raymond Osarogiagbon, MBBS, FACP, Baptist Cancer Center, Memphis, TN, comments on a real-world analysis of patients with early-stage resected non-small cell cancer (NSCLC) from a US cohort, assessing biomarker testing patterns, biomarker-targeted adjuvant therapy use, and outcomes. Testing for certain biomarkers such as ALK and EGFR differed, and lower testing and adjuvant therapy rates were observed among certain demographic and clinical subgroups. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next